Get started
Author

Amy Yamamura

Observed institution: Immuneering (United States)
ORCID: 0009-0006-7884-7633
Observed ORCID: 0009-0006-7884-7633
OpenAlex ID: A5020238460
449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors
2022 · Brett Hall, Anna Travesa, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
377 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors
2026 · Amy E Axel, Amy Yamamura, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Table S4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Data from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 6 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 5 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Table 1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS - and RAF -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al. · Cancer Research
Abstract 4195: Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models
2024 · Peter King, Jason Funt, et al. · Cancer Research
Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
2024 · Jan de Jong, Amy Yamamura, et al.
PDF
Abstract A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors
2023 · Praveen Nair, Sarah Kolitz, et al. · Molecular Cancer Therapeutics
Abstract 4124: Expressions of co-inhibitory / co-stimulatory molecules may impact immune checkpoint therapies
2019 · Pirouz M. Daftarian, Marybeth George, et al. · Cancer Research
Abstract 4124: Expressions of co-inhibitory / co-stimulatory molecules may impact immune checkpoint therapies
2019 · Pirouz M. Daftarian, Marybeth George, et al. · Clinical Research (Excluding Clinical Trials)
Works count: 21
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type